| Name | Title | Contact Details |
|---|
PaulHood goes beyond basic tax preparation. We nurture all aspects of financial health, offering peace of mind and proactive solutions tailored to your unique individual and business needs.
WE HELP ATHLETES PUSH LIMITS, CHALLENGE THE STATUS QUO AND STRIVE FOR THAT WHICH IS BEYOND THE HORIZON. Using insights from mountain athletes we have brought to market innovative products such as the Stretch Puffy Jacket focused on solving problems and delivering performance. SYNC is a fast growing performance sport brand building technical apparel for the mountain athlete. Through our single-mindedness and commitment to performance we have been able to deliver true innovation to our consumers.
After driving growth for my third VC-backed exit, Andrew Lee Miller (@andrewstartups) founded GrowthExpertz, a unique growth agency focused solely on helping tech startups in their first 12-24 months post-funding. Since 2016 weve helped over a dozen startups get to 8-9 figure valuation, several exits, and almost 100 total successful projects. We specialize in full-stack growth, handled remotely by expertz, for companies that have raised capital but still need help with marketing. We work in the background to strategize, launch and scale their organic and paid campaigns while they handle everything else. Some notable clients: www.datadistillr.com (raised $10m off of our work) www.canweapp.com (exited) www.withdouble.com (grew 30% in first 3 months) www.getemails.com (now retention.com doing $30m ARR) www.CrownDating.com (exit to Tinder/Match Group) www.denizen.io (BBVA Incubator) www.zedge.net (100m+ installs) www.different.com.au (now one of the largest startups in Australia) www.fly.com (300% increase in traffic in 12 months) www.openinvest.co (acquired by Chase) We are industry agnostic but often focus on SaaS, Fintech, Marketplace, Online Dating, Consumer Mobile Apps, and more. Email contact@growthexpertz.com or book a call at www.growthexpertz.com
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.